Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August 4, 2021

Rhea-AI Summary

Aerie Pharmaceuticals (NASDAQ: AERI) will release its Q1 2021 financial results after market close on August 4, 2021. A live conference call and webcast will follow at 5:00 PM ET to discuss the results and provide a general business update. Aerie is focused on developing innovative therapies for open-angle glaucoma and other ocular diseases, having launched its first product, Rhopressa®, in April 2018, and Rocklatan® in May 2019. The company is also expanding its global reach and developing additional candidates in ophthalmology.

Positive

• Aerie launched Rhopressa® in April 2018 and Rocklatan® in May 2019, indicating successful product introductions.
• The company focuses on global expansion and additional product candidates, reflecting growth potential.

Negative

• None.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, announced today that its first quarter 2021 financial results will be released after the market closes on Wednesday, August 4, 2021. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update.

The live webcast and a replay may be accessed by visiting the Company’s website at http://investors.aeriepharma.com. Please connect to the Company’s website at least 15 minutes prior to the live webcast to ensure adequate time for any software download that may be needed to access the webcast. Alternatively, please call (888) 734-0328 (U.S.) or (678) 894-3054 (international) to listen to the live conference call. The conference ID number for the live call is 9845827. Please dial in approximately 10 minutes prior to the call. Telephone replay will be available approximately two hours after the call. To access the replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international). The conference ID number for the replay is 9845827. The telephone replay will be available until August 12, 2021.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005067/en/

FAQ

When are Aerie Pharmaceuticals' Q1 2021 financial results being released?

Aerie Pharmaceuticals will release its Q1 2021 financial results on August 4, 2021, after market close.

What time is Aerie's financial results conference call?

The conference call for Aerie's financial results will take place at 5:00 PM ET on August 4, 2021.

What products has Aerie Pharmaceuticals launched?

Aerie Pharmaceuticals has launched Rhopressa® in April 2018 and Rocklatan® in May 2019.

What is Aerie's focus in the pharmaceutical industry?

Aerie Pharmaceuticals focuses on developing first-in-class therapies for open-angle glaucoma and ocular surface diseases.